| 摘要 |
Disclosed is a use of 0% to about 29% w/w of cis-clomiphene, and about 100% to about 71% trans-clomiphene or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of male hypogonadism, lipodystrophy, benign prostate hypertrophy or prostate cancer, wherein the medicament is to be administered non-daily to a male patient and provides a dose of from about 5 to about 100 mg/trans-clomiphene.
|
